Canbiola (CANB)

Take Impact Assessment

Impact Scorecard
About

Overall impact

B (68)

Commentary

Canbiola is a strong overall performer. With a 'B' rating of 67.8 for overall impact (78th percentile compared to all companies), Canbiola ranks 76th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 72 others, and ahead of Evolus, GenSight Biologics, Oyster Point Pharma and 75 others. On top material causes for Canbiola's industry (Pharmaceuticals & Biotech), Canbiola performs well in Child and Maternal Health (95.0 score), Humane Treatment of Animals (83.0), Child and Maternal Health (82.6) and 4 other causes where it received an 'A' score and performs poorly in Technology Innovation (18.5 score), Disaster Readiness and Effective Aid (34.9) and Reduced Green House Gas Emissions (25.8).

... read full commentary

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact

Cause			CANB

Peer rank

Overall impact

Log in to view this information

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Canbiola

Employees

Sector

Health Care

Industry

Pharmaceuticals

Sub-industry

Pharmaceuticals

SASB industry

Biotechnology & Pharmaceuticals

Headquarters

Ny, United States

Share classes

CANB

More info

https://nascentpharmaholdings.com

Description

Can B Corp. develops, manufactures, and sells hemp biomass derived products containing cannabinoids. The company provides hemp cannabinoid products, including oils, creams, moisturizers, isolate, gel caps, spa products, concentrates, and lifestyle products. It sells its products under the Canbiola and Pure Leaf Oil brands through medical professionals under distribution agreements and its website. The company also produces industrial hemp and processes hemp biomass, isolate, and isomers, such as CBN, CBG, delta-8, and delta-10. Additionally, Can B Corp. manufactures and sells durable medical equipment. The company was formerly known as Canbiola Inc. and changed its name to Can B Corp. in January 2020. Can B Corp. was incorporated in 2005 and is based in Hicksville, New York.

Material causes

Ethos considers the following causes material for Canbiola, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

Access to affordable healthcare

Ensure universal access to affordable, quality healthcare

Accountable institutions

Build accountable and inclusive institutions at all levels

Child and maternal health

End preventable deaths of mothers and children, support reproductive health everywhere

Decent, safe work opportunities

Promote full and productive employment for all, in safe work environments

Disaster readiness and effective aid

Be prepared for natural disasters and provide effective aid when disasters happen

Disease eradication

Eradicate infectious and non-communicable diseases